keyword
MENU ▼
Read by QxMD icon Read
search

Eye anti-VEGF

keyword
https://www.readbyqxmd.com/read/28445077/effect-of-epiretinal-membranes-on-antivascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#1
Han Joo Cho, Jae Min Kim, Hyoung Seok Kim, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To evaluate the effect of epiretinal membranes (ERMs), detected with spectral-domain optical coherence tomography (SD-OCT), on the outcome of antivascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD). METHODS: A total of 434 eyes with treatment-naive nAMD were retrospectively included and analyzed. All patients were administered an initial series of 3 monthly loading injections of ranibizumab or aflibercept, followed by further injections as required...
April 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28432109/early-response-to-ranibizumab-predictive-of-functional-outcome-after-dexamethasone-for-unresponsive-diabetic-macular-oedema
#2
Maria Vittoria Cicinelli, Michele Cavalleri, Lea Querques, Alessandro Rabiolo, Francesco Bandello, Giuseppe Querques
PURPOSE: To analyse the effects of intravitreal dexamethasone implant in patients suffering from diabetic macular oedema (DME) on the basis of their visual and functional response to antivascular endothelial growth factor (VEGF) loading dose, in order to early shift to corticosteroids in poorly responding patients. DESIGN: Retrospective monocentric study. METHODS: Data of patients with diabetes shifted to 0.7 mg dexamethasone implant after three injections of ranibizumab (RNB) and followed-up to 12 months were reviewed...
April 21, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28427072/anti-vascular-endothelial-growth-factor-injections-the-new-standard-of-care-in-proliferative-diabetic-retinopathy
#3
Xintong Li, Marco A Zarbin, Neelakshi Bhagat
For decades, panretinal photocoagulation (PRP) has been the standard of care for the treatment of proliferative diabetic retinopathy (PDR). The relatively recent advent of anti-vascular endothelial growth factor (VEGF) formulations for intravitreal injection has provided a fresh perspective on PDR treatment, especially in eyes with concurrent diabetic macular edema (DME). The anti-VEGF agent ranibizumab has demonstrated a potentially protective effect on eyes with DME in terms of progression to PDR in the RIDE/RISE trials, as has aflibercept in the VIVID/VISTA trials...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427068/intravitreal-steroids-in-diabetic-macular-edema
#4
Rosangela Lattanzio, Maria Vittoria Cicinelli, Francesco Bandello
Over the past decade, great strides have been made in the management of diabetic macular edema (DME). Therapeutic alternatives now include focal/grid laser photocoagulation, vitreo-retinal surgery, and intraocular injection of anti-angiogenic and steroid molecules. Intravitreal administration of steroids represents a fundamental alternative for recalcitrant and naive eyes with DME, especially in those cases when anti-vascular endothelial growth factor (VEGF) agents are contraindicated or a treatment regimen with fewer intravitreal injections is required...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427067/intravitreal-aflibercept-in-diabetic-macular-edema-long-term-outcomes
#5
Ugo Introini, Giuseppe Casalino
For decades, macular laser photocoagulation has been the standard of care in the treatment of diabetic macular edema (DME). With the relatively recent advent of anti-vascular endothelial growth factor (VEGF) agents, DME treatment has entered a new era. VEGF is a well-known pro-angiogenic and pro-permeability factor involved in the pathogenesis of DME. VEGF blockade has proven remarkably effective at reducing DME and improving visual acuity (VA) in eyes with center involved DME causing VA loss in several randomized controlled trials (RCTs)...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28424992/intravitreal-anti-vegf-treatment-for-choroidal-neovascularization-secondary-to-punctate-inner-choroidopathy
#6
T Barth, F Zeman, H Helbig, M-A Gamulescu
PURPOSE: To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. METHODS: Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed. RESULTS: Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV...
April 19, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28424147/treatment-of-leukoencephalopathy-with-calcifications-and-cysts-with-bevacizumab
#7
Alex J Fay, Allison A King, Joshua S Shimony, Yanick J Crow, Jan E Brunstrom-Hernandez
BACKGROUND: Leukoencephalopathy with calcifications and cysts is a rare, autosomal recessive cerebral microangiopathy that causes progressive white matter disease, calcifications, and cysts within the brain. It is typically associated with slowly progressive psychomotor regression, seizures, and movement disorders. Although leukoencephalopathy with calcifications and cysts affects only the central nervous system, it demonstrates remarkable neuropathologic and radiologic overlap with Coats plus, a disorder of small vessels of the brain, eyes, gastrointestinal tract, and bone...
March 23, 2017: Pediatric Neurology
https://www.readbyqxmd.com/read/28420694/caffeine-preferentially-protects-against-oxygen-induced-retinopathy
#8
Shuya Zhang, Rong Zhou, Bo Li, Haiyan Li, Yanyan Wang, Xuejiao Gu, Lingyun Tang, Cun Wang, Dingjuan Zhong, Yuanyuan Ge, Yuqing Huo, Jing Lin, Xiao-Ling Liu, Jiang-Fan Chen
Retinopathy of prematurity (ROP) is the leading cause of childhood blindness, but current anti-VEGF therapy is concerned with delayed retinal vasculature, eye, and brain development of preterm infants. The clinical observation of reduced ROP severity in premature infants after caffeine treatment for apnea suggests that caffeine may protect against ROP. Here, we demonstrate that caffeine did not interfere with normal retinal vascularization development but selectively protected against oxygen-induced retinopathy (OIR) in mice...
April 18, 2017: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/28402713/optical-biometry-derived-axial-length-measurements-following-intravitreal-anti-vascular-endothelial-growth-factor-treatment-for-macular-edema
#9
George D Kymionis, Athanassios Giarmoukakis, Ioanna K Apostolidi, Styliani V Blazaki, Konstantinos I Tsoulnaras, Joanna Moschandrea, Sofia Panagopoulou, Miltiadis K Tsilimbaris
PURPOSE: To evaluate axial length (AL) alterations in patients with macular disease over the course of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment. METHODS: In this prospective, comparative study, 33 patients with macular edema underwent unilaterally intravitreal anti-VEGF therapy and were followed for two months; the contralateral eyes were considered as controls. Central retinal thickness (CRT) was measured with spectral-domain optical coherence tomography and AL with an IOL-Master optical biometer...
April 12, 2017: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/28393562/intravitreal-anti-vegf-treatment-for-retinopathy-of-prematurity-in-infants-with-active-adenoviral-keratoconjunctivitis
#10
Yusuf Koçluk, Emine Alyamaç Sukgen
PURPOSE: To evaluate the results of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment for retinopathy of prematurity (ROP) in infants with active adenoviral keratoconjunctivitis (AKC). MATERIAL AND METHODS: A retrospective analysis was performed using the medical records of all infants treated with intravitreal injections of anti-VEGF agents during an AKC outbreak previously reported in the literature at a tertiary center for treatment of ROP...
April 10, 2017: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/28393322/anti-angiogenic-effect-of-hexahydrocurcumin-in-rat-corneal-neovascularization
#11
Chien-Neng Kuo, Ching-Hsein Chen, San-Ni Chen, Jou-Cheng Huang, Li-Ju Lai, Chien-Hsiung Lai, Chia-Hui Hung, Chien-Hsing Lee, Chung-Yi Chen
AIM: This study was to investigate the anti-angiogenic effect of hexahydrocurcumin (HHC) to evaluate gene (p-basic fibroblast growth factor (bFGF)-SAINT-18 & p-vascular endothelial growth factor (VEGF)-SAINT-18 complex)-induced corneal neovascularization (CorNV) in rats. METHODS: CorNV was induced in 24 eyes of 24 rats. Four groups (Group A: 0 μg, B: 0.01 μg, C: 0.1 μg, and D: 1 μg) of HHC were prepared and implanted into the rat subconjunctival substantia propria 1...
April 9, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28393033/combined-photodynamic-therapy-and-ranibizumab-for-polypoidal-choroidal-vasculopathy-a-2-year-result-and-systematic-review
#12
Meng Zhao, Hai-Ying Zhou, Jun Xu, Feng Zhang, Wen-Bin Wei, Ning-Pu Liu
AIM: To report a cohort of patients with polypoidal choroidal vasculopathy (PCV) treated with photodynamic therapy (PDT) followed by intravitreal ranibizumab injection 24-48h later, and to compare the results between eyes with PCV treated by PDT followed by intravitreal anti-vascular endothelial growth factor (VEGF) injection and intravitreal anti-VEGF injection followed by PDT by Meta-analysis. METHODS: Retrospective study and systematic literature review. Medical records of patients with PCV who were initially treated using PDT followed by intravitreal ranibizumab injection 24-48h after PDT and had completed at least 2y follow-up were reviewed and analyzed...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28386700/clinical-efficacy-of-anti-vegf-medications-for-central-serous-chorioretinopathy-a-meta-analysis
#13
Shangli Ji, Yemei Wei, Jiansu Chen, Shibo Tang
Background Central serous chorioretinopathy (CSC) is a widespread retinal disorder, and 30-50% of patients eventually result in retinal pigment epithelium atrophy and irreversible vision loss. Aim of the review To evaluate the effectiveness of medications based on anti-vascular endothelial growth factor (anti-VEGF) on central serous chorioretinopathy (CSC). Method A systematic search on anti-VEGF medication treatments for CSC was performed in Pubmed, Embase, and the Cochrane Library prior to May 2016. The main outcome variables were best-corrected visual acuity (BCVA) and central macular thickness (CMT)...
April 6, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/28379652/quantitative-reduction-in-central-foveal-thickness-after-first-anti-vegf-injection-as-a-predictor-of-final-outcome-in-brvo-patients
#14
Rupak Roy, Kumar Saurabh, Avirupa Ghose, Dhileesh P Chandrasekharan, Preeti Sharma, Swakshyar Saumya Pal, Sudipta Das
PURPOSE: To analyze the predictive ability of quantitative reduction in central foveal thickness (CFT) after the first antivascular endothelial growth factor (anti-VEGF) injection to assess final outcome in branch retinal vein occlusion (BRVO) patients. DESIGN: A retrospective interventional consecutive case series. METHODS: We retrospectively reviewed 60 treatment-naive BRVO patients. All the patients were treated with bevacizumab injection pro re nata...
March 29, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28377591/a-safety-study-of-high-concentration-and-high-frequency-intravitreal-injection-of-conbercept-in-rabbits
#15
Jiaming Wang, Chunyan Lei, Lifei Tao, Quan Wu, Xiao Ke, Yiguo Qiu, Bo Lei
The novel anti-VEGF drug conbercept has been used in the treatment of several retinal neovascular diseases. Owning to the alteration of the structure, the newest drug is capable of combining more molecular targets and present higher affinity to the angiogenesis promoting factors. However, it is unknown whether it will cause any unwanted effects like other anti-VEGF agents. We studied the short-term safety of high concentration and high frequency intravitreal injection of conbercept in rabbits. Intraocular pressure, fundus-photography, ERGs were applied...
April 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28376500/suppression-of-retinal-neovascularization-by-anti-ccr3-treatment-in-an-oxygen-induced-retinopathy-model-in-mice
#16
Shuichiro Hirahara, Miho Nozaki, Masaharu Ohbayashi, Norio Hasegawa, Daisuke Ozone, Yuichiro Ogura
PURPOSE: To investigate the association between retinal neovascularization and the CC chemokine receptor-3 (CCR3) in a mouse model of oxygen-induced retinopathy (OIR). METHODS: An OIR model in C57BL/6J mice was used as a retinal neovascularization model. An enzyme-linked immunosorbent assay was performed to evaluate the chronological change in vascular endothelial growth factor A (VEGF-A) and eotaxin expressions. CCR3 and VEGF subtype expression in the retina was examined using real-time RT-PCR, and CCR3, eotaxin, VEGF-A, and CD31 expression was examined immunohistochemically...
April 5, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28373914/effect-of-intravitreal-aflibercept-on-recalcitrant-diabetic-macular-edema
#17
Kendra A Klein, Tina S Cleary, Elias Reichel
BACKGROUND: Despite anti-VEGF therapy, some patients develop chronic diabetic macular edema. The objective of this study was to evaluate anatomic and visual outcomes of switching patients with chronic DME from intravitreal bevacizumab or ranibizumab to intravitreal aflibercept injection. METHODS: In this retrospective observational case series, 11 eyes with recalcitrant diabetic macular edema (DME) were evaluated 6 months prior to and 6 months following initial intravitreal aflibercept injection (IAI)...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28372860/treatment-patterns-for-myopic-choroidal-neovascularization-in-the-united-states-analysis-of-the-iris-registry
#18
Jeffrey Willis, Lawrence Morse, Susan Vitale, David W Parke, William L Rich, Flora Lum, Ronald A Cantrell
PURPOSE: To characterize treatment patterns and outcomes in eyes with treatment-naïve myopic choroidal neovascularization (mCNV) in the United States. DESIGN: Retrospective cohort study. PARTICIPANTS: Individuals aged 18 years and older seen in clinics participating in the American Academy of Ophthalmology's IRIS (Intelligent Research in Sight) Registry. METHODS: We analyzed data from the IRIS Registry, from January 1, 2012 to December 31, 2014, to identify cases of treatment-naïve mCNV, which was defined as the presence of myopic refractive error worse than -6...
March 31, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28366074/intravitreal-bevacizumab-and-dexamethasone-implant-for-treatment-of-chronic-diabetic-macular-edema
#19
Emre Güler, Yüksel Totan, Fatma Betül Güragaç
OBJECTIVE: To evaluate anatomical and functional outcomes of intraviteal bevacizumab (IVB) in patients with chronic diabetic macular edema (DME), and the effectivity and safety of dexamethasone implant in those unresponsive to regular IVB treatment. METHODS: Thirty-five eyes of 35 patients (16 male and 19 female) with chronic DME (central foveal thickness (CFT)  > 275 μm, duration  > 6 months) received three injections of 2.5 mg IVB with six-week intervals...
June 2017: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/28358962/vegf-as-a-paracrine-regulator-of-conventional-outflow-facility
#20
Ester Reina-Torres, Joanne C Wen, Katy C Liu, Guorong Li, Joseph M Sherwood, Jason Y H Chang, Pratap Challa, Cassandra M Flügel-Koch, W Daniel Stamer, R Rand Allingham, Darryl R Overby
Purpose: Vascular endothelial growth factor (VEGF) regulates microvascular endothelial permeability, and the permeability of Schlemm's canal (SC) endothelium influences conventional aqueous humor outflow. We hypothesize that VEGF signaling regulates outflow facility. Methods: We measured outflow facility (C) in enucleated mouse eyes perfused with VEGF-A164a, VEGF-A165b, VEGF-D, or inhibitors to VEGF receptor 2 (VEGFR-2). We monitored VEGF-A secretion from human trabecular meshwork (TM) cells by ELISA after 24 hours of static culture or cyclic stretch...
March 1, 2017: Investigative Ophthalmology & Visual Science
keyword
keyword
36614
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"